The research team has founded a startup called Ampera Life to commercialize the technology to detect genetic mutations and infectious agents in patients.
The assay detects a mutation that can confer hearing loss in patients, particularly neonates, who have taken gentamicin, an antibiotic prescribed for certain bacterial infections.
The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
The Fraunhofer USA team will partner with a Fraunhofer Society institute in Germany in order to reduce the cost for its patented microchip that detects viruses including Ebola.
Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.
The company has shut down the Veris molecular diagnostics product line, which Beckman Coulter spent years developing, as a result of its acquisition of Cepheid.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
